Aurobindo incurring loss at China Plant, hopes to achieve break-even by Q4

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the ...
Rediff Money

Aurobindo Pharma: China Plant Loss, Break-Even Hope

Aurobindo Pharma facing losses at China plant, expects break-even by Q4 FY26. Growth driven by Pen-G, biosimilars, and injectables.

Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

New Delhi, Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The ...